wikimedia
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
Graphs
1
Q38439446-14D0869A-7C1C-418A-A4B5-68CC45E7E6BA
Q38439446-14D0869A-7C1C-418A-A4B5-68CC45E7E6BA
BestRank
Statement
http://www.wikidata.org/entity/statement/Q38439446-14D0869A-7C1C-418A-A4B5-68CC45E7E6BA
Emerging paradigms in targeted treatments for Asian patients with NSCLC.
P2860
Q38439446-14D0869A-7C1C-418A-A4B5-68CC45E7E6BA
BestRank
Statement
http://www.wikidata.org/entity/statement/Q38439446-14D0869A-7C1C-418A-A4B5-68CC45E7E6BA
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
1922e1c4aa59a57bc52ca3a9b49d42351028a106
P2860
A phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non-small cell lung cancer after failure of prior chemotherapy and erlotinib.